Repligen Corporation $RGEN Shares Bought by Geneva Capital Management LLC

Geneva Capital Management LLC lifted its position in Repligen Corporation (NASDAQ:RGEN) by 22.4% during the third quarter, Holdings Channel reports. The institutional investor owned 596,768 shares of the biotechnology company’s stock after buying an additional 109,234 shares during the quarter. Repligen makes up approximately 1.4% of Geneva Capital Management LLC’s investment portfolio, making the stock its 23rd largest position. Geneva Capital Management LLC’s holdings in Repligen were worth $79,770,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the company. CWM LLC grew its holdings in Repligen by 67.2% during the third quarter. CWM LLC now owns 336 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 135 shares during the period. Trust Co. of Vermont acquired a new stake in Repligen in the 3rd quarter valued at about $67,000. Wilmington Savings Fund Society FSB lifted its holdings in Repligen by 2,750.0% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 513 shares of the biotechnology company’s stock valued at $69,000 after acquiring an additional 495 shares during the last quarter. Hantz Financial Services Inc. boosted its position in shares of Repligen by 92.8% during the 3rd quarter. Hantz Financial Services Inc. now owns 586 shares of the biotechnology company’s stock valued at $78,000 after purchasing an additional 282 shares in the last quarter. Finally, UMB Bank n.a. grew its stake in shares of Repligen by 17.0% in the 3rd quarter. UMB Bank n.a. now owns 666 shares of the biotechnology company’s stock worth $89,000 after purchasing an additional 97 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Insider Transactions at Repligen

In other Repligen news, Director Karen A. Dawes sold 275 shares of the company’s stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $161.00, for a total transaction of $44,275.00. Following the completion of the sale, the director directly owned 91,821 shares in the company, valued at $14,783,181. This represents a 0.30% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.20% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms recently commented on RGEN. Wells Fargo & Company dropped their target price on shares of Repligen from $190.00 to $180.00 and set an “overweight” rating on the stock in a report on Wednesday, February 25th. Barclays dropped their price target on Repligen from $200.00 to $175.00 and set an “overweight” rating on the stock in a report on Wednesday, February 25th. Weiss Ratings lowered Repligen from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Tuesday, March 3rd. Wall Street Zen lowered Repligen from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. Finally, UBS Group cut their price objective on Repligen from $200.00 to $195.00 and set a “buy” rating on the stock in a report on Wednesday, February 25th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $174.58.

Repligen Stock Down 4.8%

Shares of Repligen stock opened at $121.79 on Wednesday. Repligen Corporation has a 12-month low of $102.96 and a 12-month high of $175.77. The company has a quick ratio of 7.12, a current ratio of 8.37 and a debt-to-equity ratio of 0.26. The stock has a 50 day moving average price of $148.33 and a two-hundred day moving average price of $147.14. The stock has a market capitalization of $6.86 billion, a P/E ratio of 143.28, a PEG ratio of 2.49 and a beta of 1.14.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $0.49 earnings per share for the quarter, topping analysts’ consensus estimates of $0.44 by $0.05. Repligen had a net margin of 6.62% and a return on equity of 4.71%. The business had revenue of $197.91 million during the quarter, compared to analysts’ expectations of $192.23 million. During the same period in the previous year, the company earned $0.44 earnings per share. Repligen’s revenue for the quarter was up 18.1% on a year-over-year basis. Repligen has set its FY 2026 guidance at 1.930-2.010 EPS. Equities analysts expect that Repligen Corporation will post 1.72 earnings per share for the current year.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.